Background: Improve the treatment quality might affect patients' efficacy and survival. Methods: Five hundred thirty multiple myeloma patients treated in four hematological centers in China from February 2006 to August 2018 were enrolled. General characteristics, treatment regimens and cycles, efficacy, survival and adverse events of the patients treated before and after August 2013 (later refer to as the before-2013 and after-2013 group) were analyzed and compared. Results: The results suggested that patients who received optimized treatment regimen and route of administration completed more cycles of treatment in the after-2013 group. Although the overall response rate was similar between the two groups (88.6 vs. 90.5%), patients in the after-2013 group had higher complete remission rate (39.1 vs. 28.6%) and better progression-free survival. Subgroup analysis suggested that patients aged 65 years and older, with non-high-risk D-S, ISS, and R-ISS stages, had a significant benefit in progression-free survival. Conclusion: Therefore, in clinical practice in China, by reducing the economic burden brought by the treatment on patients and optimizing the treatment regimen, more patients can be treated with better regimens in a prolonged duration to achieve better efficacy and survival, especially in elderly and non-high-risk patients.
Background: Improve the treatment quality might affect patients' efficacy and survival. Methods: Five hundred thirty multiple myelomapatients treated in four hematological centers in China from February 2006 to August 2018 were enrolled. General characteristics, treatment regimens and cycles, efficacy, survival and adverse events of the patients treated before and after August 2013 (later refer to as the before-2013 and after-2013 group) were analyzed and compared. Results: The results suggested that patients who received optimized treatment regimen and route of administration completed more cycles of treatment in the after-2013 group. Although the overall response rate was similar between the two groups (88.6 vs. 90.5%), patients in the after-2013 group had higher complete remission rate (39.1 vs. 28.6%) and better progression-free survival. Subgroup analysis suggested that patients aged 65 years and older, with non-high-risk D-S, ISS, and R-ISS stages, had a significant benefit in progression-free survival. Conclusion: Therefore, in clinical practice in China, by reducing the economic burden brought by the treatment on patients and optimizing the treatment regimen, more patients can be treated with better regimens in a prolonged duration to achieve better efficacy and survival, especially in elderly and non-high-risk patients.
Authors: Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri Journal: Lancet Date: 2016-12-23 Impact factor: 79.321
Authors: Bertrand Arnulf; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Helgi van de Velde; Huaibao Feng; Andrew Cakana; William Deraedt; Philippe Moreau Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941
Authors: Daniel Coriu; Dominik Dytfeld; Daniela Niepel; Ivan Spicka; Imrich Markuljak; Georgi Mihaylov; Slobodanka Ostojic-Kolonic; Leah Fink; Krisztian S Toka; Katja Björklöf Journal: Pol Arch Intern Med Date: 2018-07-27
Authors: Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau Journal: Lancet Oncol Date: 2011-04-18 Impact factor: 41.316
Authors: Heinz Ludwig; Richard Greil; Tamas Masszi; Ivan Spicka; Ofer Shpilberg; Roman Hajek; Anna Dmoszynska; Bruno Paiva; María-Belén Vidriales; Graca Esteves; Anne Marie Stoppa; Don Robinson; Shalini Chaturvedi; Ozlem Ataman; Christopher Enny; Huaibao Feng; Helgi van de Velde; Luisa Viterbo Journal: Br J Haematol Date: 2015-07-07 Impact factor: 6.998